IFNA1 and glioblastoma: In a broader view, the possibility of using guadecitabine to modulate GBM phenotype making it more immunogenic and possibly more responsive to immunotherapy, is also demonstrated by the activation of a set of URs involved in immune recognition, enhancing cellular response to IFN signaling, further boosting the activation and proliferation of NK and NK T cells, critically involved in innate and adaptive immune response.